This study is testing the effectiveness and safety of a new drug combination, **Golcadomide** and **Rituximab** (Golca + R) for people with **relapsed/refractory follicular lymphoma**. Follicular lymphoma is a type of cancer that affects the lymph nodes. "Relapsed" means the cancer returned after treatment, and "refractory" means it didn't respond well to treatment. The study compares this new treatment to other treatments chosen by doctors. To join, participants must have had at least one prior treatment that included a drug targeting **CD20 proteins** on cancer cells and another drug called an alkylating agent. Participants also need to have a PET scan showing cancer presence and meet certain health criteria like having enough blood cells and good kidney function. **Key Points for Participants:** - **Length of Study:** The study involves multiple centers and is in Phase 3, indicating it's a later stage of research. - **Visits Needed:** Regular visits for treatment and monitoring are required, but exact number depends on the treatment plan. - **Compensation/Risks:** Participants may face risks from the treatment, which should be discussed with a doctor before enrolling. There is no mention of compensation.